Earlier today Citi analysts noted that AstraZeneca AZN is still the most attractive acquisition target for Pfizer PFE. However, the analysts believe there is only a 25 percent chance that Pfizer will return to the table after August 26 and instead see December as the more likely approach. The team noted an offer would need to be over $60 for Pfzer to secure the deal.
Looking at AstraZeneca, the Citi analysts say the company may potentially seek a near-term acquisition of Actelion to help boost its EPS.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in